Document Page: First | Prev | Next | All | Image | This Release | Search

File: 970101_sep96_decls31_0007.txt
Page: 0007
Total Pages: 16

Subject: REQ FOR DETERMINATION INFORMED CONSENT DRUG AND VACCINES        

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003201

Folder Title: REQUESTS FOR DETERMINATION INFORMED CONSENT DRUGS                                               

Document Number:       1001

Folder Seq  #:         16









                                                            INFORMATIONAL DROCHURE
                                                         PENTAVALENT (ABCDE) BOTULINUM               TOXOID


                                                            (IND)                            in accordance with the from @imi experiments.
                                                            requirements of the U.S. food "
                  PENTAVALENT                            (ABCDE) BOTUL I KLON Drug Adnfnistratt w (FDA). It @ tIn experiments with the orfgf@t
                                                            be                               a&lnfstered under the (at of toxofd (2,3). 30 persons
                  is      a                              coffbi net I @of almi@ supervision of qk)atifted wdicat were i@ized on a 0-2-12 week
                  Phosptiate-6dsorbed toxold 6ert@          pers@t.                                  sch@te.        Antitoxin titers were
                  f roes                                 format,in-inattivated.                      det@tabte for all 5 types of toxin
                  Partially Purified @s A,B,C, 0,           2.                               The toxofd sh@td be in about 80% of the volunteers 2
                  ard E botuti@ toxins. Each viat           administered Only to healthy mm          weeks after the third dose of the
                  contains 0.02Z% formaldehyde and          and women between the ages of 18         Initial   series.       Only a @tt
                  1:10,000                               thimerosal asaard 65 years, since investigations percentage had measurable titers by
                  preservative.                          The currently have @ conducted exclusively In @ year, just before the boosters
                  distributed toxoid is manufactured        that population.                         were given.    fight weeks after the
                        boosters, 100% of the recipients
                  P@ ic Health.                             3.                               @m The effects of had wasurable titers to all 5
                                                            Administration                   of the toxofd during @s.
                                                            pregnancy                        have not been
                                                            established.                     Data are net Since initiating the reqtjfr@t
                  SNAKE VELL before withdrawing each        available                        wthe safety of for determining antitoxin levels in
                  dose. Administer 0.5 sit of vaccfm        pentayatent botuti @ toxoid for          recipients @ for boosters, the
                  via deep subcutaneous irliect@; do        the developing fetus. There shwid        i@enicity of the toxoid in
                  net Inject intracutanmnty or into         be no risk to the fetus from the         h@m has been reaffirmed.          (only
                  s@rficiat structures. Vacci@s             pr@t itself because the toxo(d           types A, 0 andloc E ant(toxtr%s are
                  will remain in the area where the         contains Only Inactivated I>rotein.      rwti@ty assessed.)         U%fle the
                  vaccine Is &&intstered for no tees        Howver, a theoretical risk frw           antitoxin titers attained after the
                  than 30 Minutes after r@tivtrq            *ever*                           allergic reaction or 3rd shot of the initial series or*
                  each dose to v@ftor Immediate             amphytaxis                       &es exist. the likely to decline in a mtter of a
                  adverse effects.                       A 48 hour past incidence            of severe systemic few @ths, th@e "tabl lshed after
tr@ y tow (@ the first booster are relatively
                  desirable                              following each < 1%) in previous r@pi@ts (rate stable " g@ratty persist above
                  l@vtattm.                              Vacci@s should be and f@le) of this vaccine. In the detectable level for at least 2
                  informed that                          they are to report contrast.        the risk to the years. A titer of 1:16 (0.15-0.30
                  any adverse t@at wwor systmfc             ($evetopfng                      fetus of botutfm Is IU @tftoxin per at.) for either 8
                  reaction that occurs within one           prot>ably c@ iderable.           The toxofd or  E antitoxin      Is c@ fdered
                  week                                   subsequent to the should be given only to those satisf@ t@   for    deferring      a
                  adn(mistratfoo of the voccf@.          The persom                          -at risk- to booster for 2 more yes".     After
                  first injection is represented by         exposure                         of So@uti@ toxin. evel@tirg sera frm ISS recipients
                  week 0. there is a 2 week Interval        Therefore,                       inahigh-risk taken in 1986, 1987 and 1988 Who
                  between                                the first secord situation, preg@rcy should net be were d* for booster. 81 (43%) Were
                  injection and                          a 12 week tnterv&L considered a c@traindicatfw for able to postpone thm.
                  between - the                          first"third vaccination             kith botutfnum
                  injection.                                pentavat @t toxoid.                      The i@@icitfes In h@@ of
                                                                                                     the two new tots of toxoid (Lots
d a        A-2 and S-t) and of the origi@t
                  mt. deep sLA>cuta@ty at 0-                second                           or subsequent booster tot (181) were assessed by the U.S.
                  Z-IZ weeks.                               f@i tati@ @tess laboratory test          "Kedicat Research Institute for
                                                            have shown antitoxin type 6 and or       Infectious Diseases (USAXRIID) and
                  first Booster:                         0.5 ml. deep E to be bet" a satisfactory level. the results are     available   for
                  subcutaneous ty 12 K@ths after                                                     comparison     (1).     The   type     13
                  the first fnj"tiw of the initial                                                   antitoxin levels attained after     the
                  series.                                                                    IKKUNDGENICITY 3rd injection of the new tots Were
                                                            Experience                       with 1>ent6vatent significantly  higher for  the
                  Receipt of each vaccine dose will         botuti@ toxoid tas shown that-.          origi@t tot.
                  be recorded in the indivickials           (A) it is effective in protecting
                  @rw@nt vaccine file.                      animals                          against intraperit@at In 1988 USAKRIID eva t ua t ed
                  Additionally, a subset of approx.         challenge with toxins of         types   immunized       individuals         for
                  100 vacimes receiving each vaccine        A,B,C,D,                         ardEof Ctostridi mneutralizing antibodies to type A &
                  subtot                                 Witt be prospectively t@tin@. (8) the serum antitoxin 8 botuti @ toxins. After  the
as determined by Priiry series 91% had a type A
                  postcard-Wst-d qesti@ire.                 @se protection tests             correlate titer  0.08 IU/m@, ard   78% type b
                                                            with protective activity , fird (c)      titer      0.02 ]Ulmt.      After the
                                                         PRECAUTIONS the                     toxoid intr@ed into man first booster  all irdivi @ is
                  1.      Botuti@ toxoid is              m taprockxes                        levels of antitoxin tested had a d@,@trabte titer for
                  licensed pr@t and is                   distributed th@ht to be protective  as judged type A & 8 (4).
                  as      an                             investigate @t N "Drug by extrapolation of data @rived


                                                                                                     ATTACHTIENT 1

Document Page: First | Prev | Next | All | Image | This Release | Search


Document 16 f:/Week-36/BX003201/REQUESTS FOR DETERMINATION INFORMED CONSENT DRUGS/req for determination informed consent drug and :12249609312932
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = REQUESTS FOR DETERMINATION INFORMED CONSENT DRUGS
Folder Seq # = 16
Subject = REQ FOR DETERMINATION INFORMED CONSENT DRUG AND
Document Seq # = 1001
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996